Duloxen 20: Each enteric coated delayed release tablet contains 22.45 mg of Duloxetine hydrochloride INN equivalent to 20 mg of Duloxetine.
Duloxen 30: Each enteric coated delayed release tablet contains 33.68 mg of Duloxetine hydrochloride INN equivalent to 30 mg of Duloxetine.
Duloxen (Duloxetine Hydrochloride) is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) for oral administration. Duloxetine is a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors in vitro. Duloxetine does not inhibit monoamine oxidase (MAO). Orally administered Duloxetine hydrochloride is well absorbed. Elimination of Duloxetine is mainly through hepatic metabolism.
Duloxen (Duloxetine Hydrochloride) is indicated for the -
01. Treatment of Major Depressive Disorder (MDD)
02. Management of neuropathic pain associated with diabetic peripheral neuropathy.
03. Chronic Musculoskeletal Pain
04. Urinary stress incontinence.
• Major Depressive Disorder (MDD): Starting dose- 20-30 mg b.i.d or 60 mg once daily, Target dose- 60 mg once daily, max. dose- 60 mg once daily
• Diabetic peripheral neuropathy: Starting dose- 60 mg/day ( once daily), Target dose- 60 mg once daily, max. dose- 60 mg once daily
• Chronic Musculoskeletal Pain: Starting dose- 30 mg/day, Target dose- 60 mg once daily, max. dose- 60 mg once daily
• Urinary stress incontinence: Starting dose- 40 mg /day, Target dose- 80 mg/day (twice daily, max. dose- 80 mg/day (twice daily).
Use in children
Safety and efficacy in pediatric patients have not been established.
The most commonly observed adverse events in Duloxetine hydrochloride treated patients were nausea, dizziness, dry mouth, constipation, decreased appetite, fatigue, somnolence, increased sweating, hyperhidrosis and asthenia. It may slightly increase blood pressure. No clinically significant differences were observed for QT, PR, and QRS intervals between Duloxetine -treated and placebo-treated patients.
Duloxetine hydrochloride should ordinarily not be prescribed to patients with substantial alcohol use. Blood pressure should be measured prior to initiating treatment and periodically measured throughout treatment. It should be used cautiously in patients with a history of mania, seizure disorder and controlled narrow-angle glaucoma.
Pregnancy: Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women; therefore, Duloxetine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Labor and Delivery: The effect of Duloxetine on labor and delivery in humans is unknown. Duloxetine should be used during labor and delivery only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is unknown whether or not Duloxetine and/or it\'s metabolites are excreted into human milk, but nursing while on Duloxetine is not recommended.
There is limited clinical experience with Duloxetine overdose in humans. There is no specific antidote to Duloxetine. In case of acute overdose, treatment should consist of those general measures employed in the management of overdose with any drug. An adequate airway, oxygenation, and ventilation should be assured, and cardiac rhythm and vital signs should be monitored. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal may be useful in limiting absorption of Duloxetine from the gastrointestinal tract.
Duloxetine tablet should be stored in a cool (15-30 °C) and dry place away from light and out of the reach of children.
Duloxen 20: Each box contains 3 blister strips of 10 enteric coated delayed release tablets.
Duloxen 30: Each box contains 3 blister strips of 10 enteric coated delayed release tablets.
Duloxetine tablet should be swallowed whole and should not be chewed or crushed, nor should the contents be sprinkled on food or mixed with liquids. All of these might affect the enteric coating. Patients should be cautioned about operating hazardous machinery including automobiles, until they are reasonably certain that Duloxetine therapy does not affect their ability to engage in such activities.